Thus, for the development of IFN-based therapeutics for anti-obesity purposes, effective IFN regimens need to be selected and tested dynamically to overcome potential side-effects such as those manifested from antiviral IFN therapeutics [113]. This evidence concerns the gene IFNA1 and obesity due to melanocortin 4 receptor deficiency.